Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.
Researchers at the University of Liège (Belgium) have uncovered a previously unknown mechanism that regulates the immune ...
The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback